Baozhu Luo

Cancer Center And State Key Laboratory Of Biotherapy
Chengdu, 610041, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Discovery of potent ClpX modulators with pronounced antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA).

Discovery of potent ClpX modulators with pronounced antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA).

Journal: European journal of medicinal chemistry

Published: August 19, 2025

A shape complementarity strategy based on NCA029 enables potent HsClpP agonists for the treatment of small cell lung carcinoma.

A shape complementarity strategy based on NCA029 enables potent HsClpP agonists for the treatment of small cell lung carcinoma.

Journal: European journal of medicinal chemistry

Published: June 23, 2025

Discovery of 5-(Piperidin-4-yl)-1,2,4-oxadiazole Derivatives as a New Class of Human Caseinolytic Protease P Agonists for the Treatment of Hepatocellular Carcinoma.

Discovery of 5-(Piperidin-4-yl)-1,2,4-oxadiazole Derivatives as a New Class of Human Caseinolytic Protease P Agonists for the Treatment of Hepatocellular Carcinoma.

Journal: Journal of medicinal chemistry

Published: June 21, 2024

Discovery and Optimization of Novel SaFabI Inhibitors as Specific Therapeutic Agents for MRSA Infection.

Discovery and Optimization of Novel SaFabI Inhibitors as Specific Therapeutic Agents for MRSA Infection.

Journal: Journal of medicinal chemistry

Published: June 07, 2024

Rational Design of a Novel Class of Human ClpP Agonists through a Ring-Opening Strategy with Enhanced Antileukemia Activity.

Rational Design of a Novel Class of Human ClpP Agonists through a Ring-Opening Strategy with Enhanced Antileukemia Activity.

Journal: Journal of medicinal chemistry

Published: April 15, 2024

Discovery of a Novel Series of Homo sapiens Caseinolytic Protease P Agonists for Colorectal Adenocarcinoma Treatment via ATF3-Dependent Integrated Stress Response.

Discovery of a Novel Series of Homo sapiens Caseinolytic Protease P Agonists for Colorectal Adenocarcinoma Treatment via ATF3-Dependent Integrated Stress Response.

Journal: Journal of medicinal chemistry

Published: February 08, 2024

Exploration of novel isoxazole-fused quinone derivatives as anti-colorectal cancer agents through inhibiting STAT3 and elevating ROS level.

Exploration of novel isoxazole-fused quinone derivatives as anti-colorectal cancer agents through inhibiting STAT3 and elevating ROS level.

Journal: European journal of medicinal chemistry

Published: January 10, 2024

Discovery of a Novel Series of Imipridone Compounds as Homo sapiens Caseinolytic Protease P Agonists with Potent Antitumor Activities In Vitro and In Vivo.

Discovery of a Novel Series of Imipridone Compounds as Homo sapiens Caseinolytic Protease P Agonists with Potent Antitumor Activities In Vitro and In Vivo.

Journal: Journal of medicinal chemistry

Published: May 24, 2022

IMP075 targeting ClpP for colon cancer therapy in vivo and in vitro.

IMP075 targeting ClpP for colon cancer therapy in vivo and in vitro.

Journal: Biochemical pharmacology

Published: May 08, 2022

Discovery of novel indolin-2-one compounds as potent inhibitors of HsClpP for cancer treatment.

Discovery of novel indolin-2-one compounds as potent inhibitors of HsClpP for cancer treatment.

Journal: Bioorganic chemistry

Published: December 12, 2020

Human ClpP protease, a promising therapy target for diseases of mitochondrial dysfunction.

Human ClpP protease, a promising therapy target for diseases of mitochondrial dysfunction.

Journal: Drug discovery today

Published: September 08, 2020

Rapid Immobilization of Simulated Radioactive Soil Waste Using Self-Propagating Synthesized Gd₂Ti₂O₇ Pyrochlore Matrix.

Rapid Immobilization of Simulated Radioactive Soil Waste Using Self-Propagating Synthesized Gd₂Ti₂O₇ Pyrochlore Matrix.

Journal: Materials (Basel, Switzerland)

Published: February 22, 2019

Showing 1-12 of 12

Last Updated: 09/26/2026